Therapeutic Research

Abstract

Treatment recommendations for patients with secondary hyperparathyroidism（SHPT） due to chronic kidney disease have changed considerably in recent years. Active vitamin D agents have been used mainly to treat SHPT but their use raises serum calcium and phosphorus concentrations. Data from several large clinical trials indicate that cinacalcet hydrochloride substantially lowers plasma PTH levels and concurrently lowers serum calcium and phosphorus concentrations when given either alone or together with active vitamin D to patients with SHPT that are inadequately controlled despite conventional therapy. Additionally, the pleiotrophic actions such as the attenuation of cardiovascular calcification came to attract attention. The effectiveness is going to be proved further more by clinical studies including large－scale randomized controlled trials.